Scarica l'app Stockscreener
21.20
0.38%
-0.08
Dopo l'orario di chiusura:
21.30
0.10
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$21.28
Aprire:
$21.28
Volume 24 ore:
2.07M
Relative Volume:
0.45
Capitalizzazione di mercato:
$16.40B
Reddito:
$956.00K
Utile/perdita netta:
$-221.32M
Rapporto P/E:
-66.25
EPS:
-0.32
Flusso di cassa netto:
$-142.25M
1 W Prestazione:
+1.34%
1M Prestazione:
+16.39%
6M Prestazione:
+18.80%
1 anno Prestazione:
+160.44%
Intervallo 1D:
$20.62
$21.76
Intervallo di 1 settimana:
$20.27
$21.76
Portata 52W:
$6.78
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
21.20 | 16.40B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - FinancialContent
Summit Therapeutics Holds Successful 2025 Annual Meeting - TipRanks
Summit Therapeutics SMMT Sees Institutional Growth on Nasdaq Composite - Kalkine Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - GlobeNewswire Inc.
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partnrs - MarketBeat
Summit Therapeutics (SMMT) Stock Drops After Analyst's Downgrade - GuruFocus
Kalkine : Summit Therapeutics Slides as Nasdaq Index Remains Largely Steady - Kalkine Media
Summit Therapeutics (SMMT) Receives Underperform Rating from Lee - GuruFocus
Why Summit Therapeutics Stock Tanked Today - Barchart.com
U.S. Markets Closed Mixed Wednesday As SailPoint Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Faces Analytical Downgrade on Drug Prospects - GuruFocus
Merck rival Summit draws a rare sell-equivalent rating - Seeking Alpha
Summit Therapeutics (SMMT) Receives New Analyst Coverage from Leerink Partners | SMMT Stock News - GuruFocus
Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target - marketscreener.com
Summit Therapeutics at Goldman Sachs Healthcare Conference: Strategic Advances in Cancer Treatment - Investing.com Canada
Transcript : Summit Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 01 - MarketScreener
Truist Sticks to $35 Target on Summit (SMMT) Despite Shifting Deal Landscape - MSN
Why is Summit stock in selloff after late-stage trial data for lead asset? - MSN
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday - MSN
Wellington Management Group LLP Sells 4,069 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Brokerages Set Summit Therapeutics Inc. (NASDAQ:SMMT) Target Price at $37.40 - Defense World
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SMMT Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brown-Forman Corporation - GlobeNewswire Inc.
Summit Therapeutics Expands Team with $1.2M Stock Options Package for 7 New Hires - Stock Titan
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | SMMT Stock News - GuruFocus
Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Yahoo Finance
2 Soaring Stocks Wth More Upside Potential - AOL.com
Ameriprise Financial Inc. Acquires New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns "Market Outperform" Rating from JMP Securities - MarketBeat
Investors Are Dumping These 10 Stocks - Insider Monkey
Why Summit Therapeutics Inc. (SMMT) Crashed Last Week - MSN
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday - MSN
Summit Therapeutics: What's This Ivonescimab Rollercoaster - Nasdaq
10 Stocks Leaving Wall Street in The Dust - Insider Monkey
Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer (NASDAQ:SMMT) - Seeking Alpha
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround - Yahoo Finance
Summit Therapeutics: Market Overreaction Creates Opportunity (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results - sharewise
Summit Therapeutics (SMMT) Gains Attention Following Positive Ph - GuruFocus
Summit Therapeutics (SMMT) Gains Attention Following Positive Phase III Trial Results | SMMT Stock News - GuruFocus
SMMT: Summit Therapeutics' Market Outperform Rating Reiterated by JMP Securities | SMMT Stock News - GuruFocus
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
3.00%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):